Esperion Therapeutics, Inc. (ESPR) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↑
17.14
-1% vs avg
5yr avg: 17.40
30Y Low15.8·High19.0
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
30Y Low1.2·High81.0
ROE
N/A
—
5yr avg: N/A
30Y Low-487%·High-24%
Debt/EBITDA
↓
9.08
↓-9% vs avg
5yr avg: 9.97
30Y Low9.1·High10.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ESPR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Esperion Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $655M | $769M | $412M | $308M | $414M | $145M | $714M | $1.6B | $1.2B | $1.6B | $282M |
| Enterprise Value | $1.0B | $1.1B | $858M | $767M | $550M | $196M | $595M | $1.5B | $1.2B | $1.5B | $247M |
| P/E Ratio → | -28.64 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.62 | 1.91 | 1.24 | 2.65 | 5.48 | 1.84 | 3.14 | 10.89 | 6.67 | — | — |
| P/B Ratio | — | — | — | — | — | — | — | 80.97 | — | 6.44 | 1.23 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ESPR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Esperion Therapeutics, Inc.'s enterprise value stands at 17.1x EBITDA, roughly in line with its 5-year average of 17.4x. The Healthcare sector median is 14.2x, placing the stock at a 21% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.85 | 2.58 | 6.59 | 7.29 | 2.50 | 2.61 | 9.78 | 6.47 | — | — |
| EV / EBITDA | 17.14 | 19.03 | 15.76 | — | — | — | — | — | — | — | — |
| EV / EBIT | 17.17 | 19.07 | 114.34 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ESPR Profitability
Margins and return-on-capital ratios measuring operating efficiency
Esperion Therapeutics, Inc. earns an operating margin of 15.0%. Operating margins have expanded from -133.7% to 15.0% over the past 3 years, signaling improving operational efficiency. ROIC of 66.5% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.9% | 67.9% | 79.4% | 62.8% | 64.3% | 81.9% | 98.9% | 100.0% | 99.9% | — | — |
| Operating Margin | 15.0% | 15.0% | 16.4% | -133.7% | -237.8% | -289.0% | -53.3% | -62.8% | -110.9% | — | — |
| Net Profit Margin | -5.6% | -5.6% | -15.6% | -179.9% | -309.6% | -343.0% | -63.1% | -65.5% | -109.4% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | -487.0% | — | -70.6% | -29.1% |
| ROA | -5.6% | -5.6% | -18.8% | -92.2% | -74.2% | -73.2% | -50.6% | -54.3% | -95.8% | -63.9% | -27.7% |
| ROIC | 66.5% | 66.5% | 132.8% | — | — | — | — | — | — | -62.7% | -28.0% |
| ROCE | 45.9% | 45.9% | 73.9% | -151.6% | -77.4% | -79.9% | -59.6% | -81.9% | -126.4% | -71.3% | -29.3% |
ESPR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Esperion Therapeutics, Inc. carries a Debt/EBITDA ratio of 9.1x, which is highly leveraged (182% above the sector average of 3.2x). Net debt stands at $380M ($548M total debt minus $168M cash). Interest coverage of just 0.7x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | 0.08 | — | 0.00 | 0.01 |
| Debt / EBITDA | 9.08 | 9.08 | 10.85 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — | — | -8.25 | — | -0.14 | -0.16 |
| Net Debt / EBITDA | 6.30 | 6.30 | 8.20 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 0.71 | 0.71 | 0.13 | -2.55 | -3.11 | -4.81 | -5.33 | -10.97 | -2045.85 | -842.37 | -198.41 |
ESPR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.56x is below 1.0, meaning current liabilities exceed current assets. The quick ratio of 0.21x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 1.29x to 0.56x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.56 | 0.56 | 1.37 | 1.29 | 2.67 | 4.48 | 3.68 | 3.20 | 2.22 | 6.15 | 13.70 |
| Quick Ratio | 0.21 | 0.21 | 0.99 | 0.87 | 2.29 | 4.02 | 3.51 | 3.20 | 2.22 | 6.15 | 13.70 |
| Cash Ratio | 0.56 | 0.56 | 0.59 | 0.53 | 1.81 | 3.54 | 3.24 | 3.04 | 0.57 | 1.04 | 2.45 |
| Asset Turnover | — | 0.87 | 0.97 | 0.57 | 0.30 | 0.21 | 0.64 | 0.69 | 1.29 | — | — |
| Inventory Turnover | 1.23 | 1.23 | 0.73 | 0.66 | 0.77 | 0.41 | 0.15 | — | — | — | — |
| Days Sales Outstanding | — | 126.93 | 88.02 | 152.15 | 163.11 | 106.71 | 19.87 | — | — | — | — |
ESPR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Esperion Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 7.7% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 7.7% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $208M | $187M | $103M | $66M | $29M | $27M | $27M | $27M | $24M | $23M |
Peer Comparison
Compare ESPR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ESPRYou | $655M | -28.6 | 17.1 | — | 67.9% | 15.0% | — | 66.5% | 9.1 |
 MDGL | $12B | -39.4 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 EWTX | $4B | -22.6 | — | — | — | — | -34.2% | -32.4% | — |
 PRTA | $468M | -2.0 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 RARE | $3B | -4.7 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 ACAD | $4B | 9.4 | 25.7 | 35.2 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 AMRN | $333M | -8.9 | — | 49.4 | 56.6% | -6.5% | -8.2% | -2.9% | — |
 AKRO | $4B | -14.6 | — | — | — | — | -39.2% | -55.3% | — |
 LNTH | $7B | 30.5 | 16.8 | 19.1 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 NUVL | $9B | -21.1 | — | — | — | — | -36.7% | -32.5% | — |
 HALO | $8B | 26.8 | 11.2 | 12.6 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 19 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ESPR — Frequently Asked Questions
Quick answers to the most common questions about buying ESPR stock.
What is Esperion Therapeutics, Inc.'s P/E ratio?
Esperion Therapeutics, Inc.'s current P/E ratio is -28.6x. This places it at the 50th percentile of its historical range.
What is Esperion Therapeutics, Inc.'s EV/EBITDA?
Esperion Therapeutics, Inc.'s current EV/EBITDA is 17.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.4x.
Is ESPR stock overvalued?
Based on historical data, Esperion Therapeutics, Inc. is trading at a P/E of -28.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Esperion Therapeutics, Inc.'s profit margins?
Esperion Therapeutics, Inc. has 67.9% gross margin and 15.0% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Esperion Therapeutics, Inc. have?
Esperion Therapeutics, Inc.'s Debt/EBITDA ratio is 9.1x, indicating high leverage. A ratio above 4x may signal elevated financial risk.